According to
GuruFocus Insider Data
, these are the largest CEO buys during the past week. The
overall trend of CEOs is illustrated in the chart below:
Susser Petroleum (
SUSP
): CEO and Chairman of the Board Sam L. Susser Bought 351,220
Shares
CEO and Chairman of the Board of (
SUSP
) Susser Petroleum Partners Sam L. Susser bought 351,220 shares
on 09/25/2012 at an average price of $24. Susser Petroleum
Partners LP is primarily engaged in fee-based wholesale
distribution of motor fuels to Susser Holdings Corporation and
third parties. Susser Petroleum has a market cap of $262.53
million; its shares were traded at around $24 .
SUSP recently reported strong financial and operating results for
the second quarter ended July 1, 2012. Same-store merchandise
sales increased by 8 percent, compared with growth of 5.8 percent
in the prior-year period. Average retail gallons per store also
increased 8 percent year-over-year, versus growth of 3.6 percent
a year earlier.
Executive Vice President, CFO and Treasurer
Mary E. Sullivan
bought 25,000 shares of SUSP stock on 09/25/2012 at the average
price of $20.5. Mary E. Sullivan owns at least 5,000 shares after
this. The price of the stock has increased by 17.07% since. Other
insiders have also increased their positions in the company.
Rovi Corporation (
ROVI
): President and CEO Tom Carson Bought 15,000 Shares
President and CEO of Rovi Corporation (
ROVI
) Tom Carson bought 15,000 shares on 09/25/2012 at an average
price of $14.51. Rovi Corporation, formerly Macrovision Solutions
Corporation, provides a set of solutions that enable businesses
to protect, enable and distribute their digital goods to
consumers and allows consumers the ability to discover and manage
digital media across multiple channels. Rovi Corporation has a
market cap of $1.58 billion; its shares were traded at around
$14.51 with a P/E ratio of 11.61 and P/S ratio of 2.29. Rovi
Corporation had an annual average earnings growth of 6.1% over
the past 10 years. GuruFocus rated Rovi Corporation
the business predictability rank of 2.5-star
.
Jean-Marie Eveillard
owns 184 shares as of 06/30/2012, which accounts for less than
0.01% of the $25.72 billion portfolio of First Eagle Investment
Management LLC. PRIMECAP Management sold out his holdings in the
quarter that ended on 06/30/2012.
CFO Peter Halt sold 2,691 shares of ROVI stock on 09/04/2012 at
the average price of 14.16. Peter Halt owns at least 58,757
shares after this. The price of the stock has increased by 2.47%
since.
Zale Corporation (
ZLC
): CEO Theo Killion Bought 4,000 Shares
CEO of Zale Corporation (
ZLC
) Theo Killion bought 4,000 shares on 09/24/2012 at an average
price of $6.9. Zale Corporation is a specialty retailer of fine
jewelry. Zale Corporation has a market cap of $222.32 million;
its shares were traded at around $6.9 with and P/S ratio of 0.12.
Zale recently reported its fiscal fourth quarter 2012 financial
results. Revenues were $407 million, an increase of $30 million,
or 7.9 percent, compared to $377 million in the fourth quarter of
fiscal 2011.
10% Owner Capital Management LLC Breeden sold 256,343 shares of
ZLC stock on 05/15/2012 at the average price of 2.27. Capital
Management LLC Breeden owns at least 5,679,071 shares after this.
Midway Gold Corp. (
MDW
): President and CEO Kenneth Arnold Brunk Bought 12,000
Shares
President and CEO of Midway Gold Corp. (
MDW
) Kenneth Arnold Brunk bought 12,000 shares on 09/25/2012 at an
average price of $1.64. Midway Gold Corp. is a precious metals
company with a vision to explore, design, build, and operate gold
mines. Midway Gold Corp. has a market cap of $209.71 million; its
shares were traded at around $1.64 .
Chris Davis owns 25,000 shares as of 06/30/2012, which accounts
for less than 0.01% of the $43.07 billion portfolio of Davis
Selected Advisers.
Progenics Pharmaceuticals Inc. (
PGNX
): CEO Mark Robert Baker Bought 1,036 Shares
CEO of Progenics Pharmaceuticals Inc. (
PGNX
) Mark Robert Baker bought 1,036 shares on 09/26/2012 at an
average price of $2.88. Progenics Pharmaceuticals Inc. is a
biopharmaceutical company focusing on the development &
commercialization of innovative therapeutic products to treat the
unmet medical needs of patients with debilitating conditions and
life-threatening diseases. Progenics Pharmaceuticals Inc. has a
market cap of $97.58 million; its shares were traded at around
$2.88 with and P/S ratio of 1.15.
PGNX recently reported its second quarter 2012 financial results.
Net loss for the quarter was $10.7 million or $0.32 basic and
diluted per share, compared to net income of $55.5 million or
$1.64 per share in 2011.
Senior Vice President Medical Affairs Robert J. Israel sold 1,000
shares of PGNX stock on 07/02/2012 at the average price of $9.79.
Robert J. Israel owns at least 35,050 shares after this. The
price of the stock has decreased by 70.58% since. Other insiders
have also increased their positions in the company.
For the complete list of stocks that bought by their company
CEOs, go to:
[url=http://www.gurufocus.com/InsiderBuy.php?position=ceo]CEO
Buys[/url].About GuruFocus: GuruFocus.com tracks the stocks picks
and portfolio holdings of the world's best investors. This value
investing site offers stock screeners and valuation tools. And
publishes daily articles tracking the latest moves of the world's
best investors. GuruFocus also provides promising stock ideas in
3 monthly newsletters sent to
Premium Members
.